SCHEMBL3156629

SCHEMBL3156629

Cc1cn2cccnc2n1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 15/20 0.57
KDM4E B2RXH2 14/20 0.57
RAB9A P51151 11/20 0.57
NPC1 O15118 10/20 0.57
GAA P10253 5/20 0.57
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
HPGD P15428 10/20 0.53
GLA P06280 4/20 0.53
HSD17B10 Q99714 4/20 0.53
SMN1; SMN2 Q16637 7/20 0.50
NPSR1 Q6W5P4 1/20 0.50
POLB P06746 2/20 0.49
MAPT P10636 2/20 0.49
TP53 P04637 1/20 0.49
RCE1 Q9Y256 1/20 0.47
GFER P55789 1/20 0.45
PKM P14618 1/20 0.44
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23407555 0.77 ALDH1A1 (0.68) ALDH1A1KDM4ERAB9ANPC1GAA
SCHEMBL22228649 0.76 ALDH1A1 (0.61) ALDH1A1KDM4ERAB9ANPC1GAA
SCHEMBL30302269 0.76 ALDH1A1 (0.61) ALDH1A1KDM4ERAB9ANPC1GAA
SCHEMBL30523201 0.75 ALDH1A1 (0.53) ALDH1A1KDM4ERAB9ANPC1GAA
SCHEMBL22448220 0.75 ALDH1A1 (0.53) ALDH1A1KDM4ERAB9ANPC1GAA
SCHEMBL3156623 0.75 ALDH1A1 (0.53) ALDH1A1KDM4ERAB9ANPC1GAA
SCHEMBL23090057 0.75 ALDH1A1 (0.57) ALDH1A1KDM4ERAB9ANPC1GAA
SCHEMBL17950071 0.75 ALDH1A1 (0.53) ALDH1A1KDM4ERAB9ANPC1GAA
SCHEMBL8811701 0.75 ALDH1A1 (0.57) ALDH1A1KDM4ERAB9ANPC1GAA
SCHEMBL14315159 0.75 RAB9A (0.57) ALDH1A1KDM4ERAB9ANPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
US-5538997-A HIV PROTEINASE INHIBITORS SANDOZ LTD. (CH) 1996-07-23 US claimed
EP-0615969-A1 2,4-Diamino-3-hydroxycarboxylic acid derivatives SANDOZ LTD. (CH) 1994-09-21 EP claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
US-20240409557-A1 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS AMGEN INC. (US) 2024-12-12 US disclosed
EP-4289813-A2 INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION Global Blood Therapeutics, Inc. (US) 2023-12-13 EP disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230355705-A1 DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS THE UNIVERSITY OF HONG KONG (CN) 2023-11-09 US disclosed
US-20230329100-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2023-10-12 US disclosed
US-11730810-B2 Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-08-22 US disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056210-A2 DIPHENYLMETHANE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK & CO., INC. (US) 2007-05-18 WO disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed
US-7179922-B2 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders ASTRAZENECA AB (SE) 2007-02-20 US disclosed
US-7179922-B2 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders ASTRAZENECA AB (SE) 2007-02-20 US disclosed
US-20060189631-A1 Substituted imidazopyrimidines for the prevention and treatment of cancer LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-08-24 US disclosed
US-5538997-A HIV PROTEINASE INHIBITORS SANDOZ LTD. (CH) 1996-07-23 US disclosed
EP-0615969-A1 2,4-Diamino-3-hydroxycarboxylic acid derivatives SANDOZ LTD. (CH) 1994-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230329100-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SAT1, SLC1A2, SLC18A1 ALDH1A1 121/4885KDM4E 897/4885RAB9A 2664/4885
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 ALDH1A1 2159/4885KDM4E 3267/4885RAB9A 1213/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH ALDH1A1 587/4885KDM4E 3565/4885RAB9A 1784/4885
US-20060189631-A1 Substituted imidazopyrimidines for the prevention and treatment of cancer BRCA1, CCNA1, DPYD ALDH1A1 8/4885KDM4E 3211/4885RAB9A 3442/4885
US-11730810-B2 Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response CD4, MYD88, STING1 ALDH1A1 2611/4885KDM4E 3625/4885RAB9A 3072/4885
US-20240409557-A1 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS HPGD, ADH1A, ADH5 ALDH1A1 65/4885KDM4E 2813/4885RAB9A 2540/4885
US-20230355705-A1 DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS YEATS2, YEATS4, KNTC1 ALDH1A1 3939/4885KDM4E 351/4885RAB9A 3446/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP ALDH1A1 312/4885KDM4E 2437/4885RAB9A 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.